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Purpose: We developed an absolute risk model to identify individuals in the general population at elevated risk of
pancreatic cancer.
Patients and Methods: Using data on 3,349 cases and 3,654 controls from the PanScan Consortium, we developed a relative
risk model for men and women of European ancestry based on non-genetic and genetic risk factors for pancreatic cancer.
We estimated absolute risks based on these relative risks and population incidence rates.
Results: Our risk model included current smoking (multivariable adjusted odds ratio (OR) and 95% confidence interval: 2.20
[1.84–2.62]), heavy alcohol use (.3 drinks/day) (OR: 1.45 [1.19–1.76]), obesity (body mass index .30 kg/m
2) (OR: 1.26 [1.09–
1.45]), diabetes .3 years (nested case-control OR: 1.57 [1.13–2.18], case-control OR: 1.80 [1.40–2.32]), family history of
pancreatic cancer (OR: 1.60 [1.20–2.12]), non-O ABO genotype (AO vs. OO genotype) (OR: 1.23 [1.10–1.37]) to (BB vs. OO
genotype) (OR 1.58 [0.97–2.59]), rs3790844(chr1q32.1) (OR: 1.29 [1.19–1.40]), rs401681(5p15.33) (OR: 1.18 [1.10–1.26]) and
rs9543325(13q22.1) (OR: 1.27 [1.18–1.36]). The areas under the ROC curve for risk models including only non-genetic factors,
only genetic factors, and both non-genetic and genetic factors were 58%, 57% and 61%, respectively. We estimate that
fewer than 3/1,000 U.S. non-Hispanic whites have more than a 5% predicted lifetime absolute risk.
Conclusion: Although absolute risk modeling using established risk factors may help to identify a group of individuals at
higher than average risk of pancreatic cancer, the immediate clinical utility of our model is limited. However, a risk model
can increase awareness of the various risk factors for pancreatic cancer, including modifiable behaviors.
Citation: Klein AP, Lindstro ¨m S, Mendelsohn JB, Steplowski E, Arslan AA, et al. (2013) An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic
Cancer in the General Population. PLoS ONE 8(9): e72311. doi:10.1371/journal.pone.0072311
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Introduction
Pancreatic Cancer is the 4
th leading cause of cancer death in the
United States [1]. While the lifetime risk (age 85) of pancreatic
cancer for US Caucasians is only 1.5% [1], the five-year survival
rate is less than 4.8%, the poorest of any major tumor type [1].
The primary reason for the poor survival rate is the high
proportion of patients (.80%) who are diagnosed with locally
advanced or metastatic disease. However, five-year survival rates
for patients with early-stage resectable disease can exceed 20%
[1,2], underscoring the need to improve early detection. Numer-
ous studies are underway to identify and validate promising
biomarkers [3,4] for early detection. In addition, several clinical
studies have shown that imaging via e ndoscopic ultrasound, MRI
or CT scan can detect pre-cancerous changes in the pancreas
among high-risk individuals [5–8].
Given the low incidence of pancreatic cancer in the general
population, widespread screening may not be practically feasible,
even with a highly sensitive and specific test. Therefore,
identification of individuals with substantially elevated risk will
be important to the success of early detection studies. Pancreatic
cancer tends to cluster in families and the heritability has been
estimated to 0.36, indicating a strong genetic influence [9].
Although high-penetrance germline mutations have been identi-
fied, they only explain a small fraction of cases (less than 5%),
indicating that many susceptibility variants (rare and common)
remains to be identified. There appears to be no demographic
differences between sporadic and familial pancreatic cancers.
While there has been some suggestion that familial pancreatic
cancers may have a slightly earlier age-of-onset (approximately 5
years) this finding has been inconsistent [10,11]. No differences in
the pathology of invasive pancreatic cancers in patients with
familial vs non-familial pancreatic cancers have been reported [12]
(A. Klein, unpublished work). However, non-invasive precursors
are more common in patients with familial pancreatic cancer and
these precursor lesions of higher-grade than the lesions that occur
in patients without a family history [12]
Pancreatic cancer risk has been associated with cigarette
smoking [13], heavy alcohol use [14,15], diabetes mellitus [16],
increased body mass index [17], family history of pancreatic
cancer [18] and inherited genetic variation. Germline mutations in
several genes, BRCA2, PALB2, p16, ATM, STK11, PRSS1, SPINK1
and DNA mis-match repair, have been associated with an
increased pancreatic cancer risk [19–26]. In addition, two recently
completed genome-wide association studies (GWAS), PanScan1
and PanScan2, have identified variants in ABO (rs505922), 1q32.1
(rs3790844), 13q22.1 (rs9543325) and 5p15.3 (rs401681) that are
associated with a modestly increased risks of pancreatic cancer
[27,28]. The ABO single nucleotide polymorphism (SNP) rs505922
is in strong linkage disequilibrium with O/non-O blood group
alleles indicating that individuals with non-O blood groups are at
an increased risk of developing pancreatic cancer [29,30]. In
addition, haplotypes of SNPs rs505922 and rs8176746 are
perfectly correlated with the O and B alleles, respectively
[29,30], and the assessment of both SNPs allow for complete
discrimination between blood groups.
The aim of this study was to derive an absolute risk model for
pancreatic cancer in the general population. By using data from
both prospective cohort studies and retrospective case-control
studies, we developed a relative risk model that included
established risk factors for pancreatic cancer. We then estimated
participants’ absolute risk of developing pancreatic cancer by
combining the derived risk model with incidence data from the
SEER registries.
Methods
Study Population
The PanScan Consortium is comprised of 12 case-control
studies nested within prospective cohorts and 8 retrospective case-
control studies that participated in two GWAS of pancreatic
cancer [27,28]. The cohorts include: The Alpha-Tocopherol Beta-
Carotene Prevention Study (ATBC), Give us a Clue to Cancer and
Heart Disease Study (CLUEII), Cancer Prevention Study (CPSII),
European Prospective Investigation Into Cancer and Nutrition
Study (EPIC), Health Professionals Follow-Up Study (HPFS),
Nurses’ Health Study (NHS), The New York University, Women’s
Health Study (NYU-WHS), Physicians Health Study (PHS),
Prostate, Lung, Colorectal Ovarian Cancer Screening Trial
(PLCO), Shanghai Men’s and Women’s Health Study (SMWHS),
Women’s Health Initiative (WHI), and the Women’s Health Study
(WHS). The retrospective case-control studies were conducted at
the Mayo Clinic, Yale University (Connecticut Pancreas Cancer
Case Control Study), Group Health (Seattle Puget Sound) and
Kaiser Permanente in Northern California (PACIFIC Study),
Memorial Sloan Kettering Cancer Center, MD Anderson Cancer
Center, University of California San Francisco, Johns Hopkins
Medical School, and Mount Sinai Toronto.
Ethics Statement
The Institutional Review Boards approval, including approval
of the consent procedure, was obtained for each of the studies as
follows: ATBC and Ag.Health (National Cancer Institute Special
Studies Institutional Review Board (SSIRB)), CLUE (Johns
Hopkins School of Public Health (JHSPH) Institutional Review
Board Office), CPS II (Emory University Institutional Review
Board), EPIC (International Agency for Research on Cancer
(IARC) Institutional Review Board Office), HPFS, WHS, NHS
and PHS (Partners Healthcare System, Human Research Com-
mittee, Partners Human Research Office), PLCO (National
Cancer Institute Special Studies Institutional Review Board
(SSIRB)), SMWHS (Vanderbilt University Institutional Review
Board), WHI (Fred Hutchinson Cancer Research Center Institu-
tional Review Board), Group Health – PACIFIC (Group Health
Research Institute, Human Subjects Review Office), JHU (Johns
Hopkins Medicine, Office of Human Subjects Research, Institu-
tional Review Board), MAYO (Mayo Clinic Institutional Review
Board), MDA (MD Anderson Cancer Center, Office of Protocol
Research, Institutional Review Board), MSKCC (Memorial
Sloan-Kettering Cancer Center, Institutional Review Board/
Privacy Board), TORONTO (University Health Network,
Research Ethics Board),(UCSF) University of California San
Francisco, Human Research Protection Program, Committee on
Human Research, YALE (Yale University, Human Investigation
Committee). Written consent was obtained from all study
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the coordinating center for the PanScan I and II studies, the
National Cancer Institute Special Studies Institutional Review
Board (SSIRB) reviewed and approved the PanScan protocol in its
entirety.
A brief description of each study is provided in Tables S1 and
S2. Genotype and covariate data were available for 3,851 cases
and 3,924 controls. Analyses were restricted to non-Hispanic
whites as four percent of study participants reported non-
European ancestry (n=493), precluding meaningful analyses
within this subgroup. Participants with diabetes diagnosed
(n=467) within 3 years of pancreatic cancer diagnosis were
excluded because of possible reverse causation. To ascertain
potential confounding effects of diabetes proximal to pancreatic
cancer diagnosis, we conducted sensitivity analyses including/
excluding these participants as well as modeling an indicator
variable denoting diabetes diagnosis within three years prior to
pancreatic cancer diagnosis. Point estimates for the other key
risk factors were not substantially changed among the models. A
total of 3,349 cases and 3,654 controls were included in our
analyses.
Description of covariate and SNP data
For each study, we collected information on age, sex, ethnicity,
cigarette smoking history (never/former/current), history of
diabetes mellitus (never/.3 years duration), body mass index
(BMI, #30/.30), heavy alcohol consumption (#3 drinks per
day/.3 drinks per day), and family history of pancreatic cancer
(yes/no). Age was defined as age at diagnosis for cases and age at
interview for controls (Table 1). The following criteria were used to
select risk factors for inclusion in the model 1) factor has been
consistently associated with pancreatic cancer risk and 2) data was
available from both the case-control and cohort studies. Missing
covariate data were modeled using the missing indicator method
where a separate ‘missing’ level is created within each covariate.
Details on data collection for the various covariates have been
described in previous publications [15,17,31,32] Genotyping in
PanScan has been described earlier [27,28]. ABO alleles were
derived from genotypes for rs505922 and rs8176746 as described
previously [30]. Complete case analysis was conducted for the
genotype data; the small number of participants for whom data
were missing on at least one of the genetic markers (n=6) were
excluded from any analyses that included genetic risk factors.
Statistical Methods
Before pooling data from the cohort and case-control studies,
logistic regression models were fit separately to both the case-
control and cohort data. We compared OR estimates for each risk
factor from the case-control and cohort studies and looked for
substantive differences. With the exception of history of diabetes
mellitus, no substantive differences were observed. Data were
pooled in the subsequent analysis.
To build a relative risk model for pancreatic cancer, we fit a
logistic regression model for case-control status as a function of
smoking history, history of diabetes, family history of pancreatic
cancer, alcohol consumption, obesity and GWAS-identified risk
markers including ABO blood group, adjusted for sex, age and
study. In particular, we fit the following logistic regression
model:
logit½Pr(Case) ~azbsexXsexzb
T
ageXagezb
T
studyXstudyz
b
T
smokingXsmokingzb
T
diabetesXdiabetesz
b
T
famhxXfamhxzb
T
drinkingXdrinkingz
b
T
BMIXBMIzb
T
ABOXABOz
b1q32X1q32zb1q32X1q32z
b5p15X5p15zb13q22X13q22
The terms Xage, Xstudy, Xsmoking et cetera are vectors of categorical
indicator variables, corresponding to the categories in Tables 1
and 2. For example, a former smoker would have Xsmoker=(1,0,0)
T,
while a never smoker would have Xsmoker=(0,0,0)
T. The SNPs
X1q32, X5p15 and X13q22 were coded as counts of risk alleles, and Xsex
was an indicator for female sex. We modeled the effect of history
of diabetes mellitus separately for retrospective case-control and
prospective nested case-control studies.
Given estimates of the log odds ratios, we calculated the relative
risk for an individual with a specific risk profile X~(XT
smoking,
XT
diabetes,XT
famhx,XT
drinking,XT
BMI,XT
ABO,X1q32,X5p15,X13q22)
T as
follows:
RR(X)~exp½b
T
smokingXsmokingzb
T
diabetesXdiabeteszb
T
famhxXfamhxz
b
T
drinkingXdrinkingzb
T
BMIXBMIzb
T
ABOXABOz
b1q32X1q32zb1q32X1q32zb5p15X5p15zb13q22X13q22 
This relative risk model was then used to calculate Receiver
Operating Characteristic (ROC) curves (by comparing the
distribution of ORs in cases versus controls) and age-specific
incidence rates (described below). We also fit relative risk models a)
excluding the genetic factors and b) including only the genetic
factors, in order to compare the relative contribution of genetic
and non-genetic factors to risk prediction.
We calculated the area under the ROC curves using the Mann-
Whitney statistic and compared the areas for different models
using the method described by DeLong et al. [33] as implemented
in SAS PROC LOGISTIC. These calculations were performed in
the subset of data with no missing genetic or non-genetic covariate
data (435 cases and 458 controls from the cohort studies and 885
cases and 1,093 controls from the case-control studies).
Age-specific incidence for an individual with risk factor profile
X was calculated as rSEX(t) RR(X), where the sex-specific baseline
incidence rate rSEX(t) was calculated as the appropriate sex-and
age-specific average incidence rate divided by the average relative
risk in controls with no missing covariate data [34]. Average
incidence rates by age for white men and women were based on
SEER (Surveillance, Epidemiology and End Results, http://seer.
cancer.gov/) data for years 2000–2008 (SEER17). The baseline
incidence was the incidence among participants who had never
smoked, had never been diagnosed with diabetes, had no family
history of pancreatic cancer, drank an average of #3 alcoholic
drinks/day, had an adult BMI between 18.5 and 25, and did not
carry any of the risk alleles at the four known risk loci. Lifetime
risks were calculated by integrating the age-specific incidence
rates, accounting for mortality due to other causes [34,35].
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Characteristic Cohort Case-Control
Cases n (%) Controls n (%) Cases n (%) Controls n (%)
Sex
Male 676 (50) 732 (51) 1076 (54) 1171 (53)
Female 667 (50) 713 (49) 930 (46) 1038 (47)
Age in years categories
,50 39 (3) 20 (1) 184 (9) 219 (10)
51–60 185 (14) 161 (11) 498 (25) 494 (22)
61–65 241 (18) 239 (17) 339 (17) 361 (16)
66–70 290 (22) 349 (24) 328 (16) 366 (16)
71–75 290 (22) 349(24) 299 (15) 369 (17)
76–80 200(15) 224(16) 225 (11) 270 (12)
81+ 98(7) 103(7) 133 (7) 130 (6)
Cigarette smoking status
Never smoker 768(59) 902(63) 661 (39) 900 (48)
Former smoker 357(27) 405(28) 772 (45) 820 (44)
Current smoker 176(14) 116(8) 270 (15) 154 (8)
Missing/Not Available 42 22 293 315
Diabetes mellitus
Never 1147(93) 1309 (95) 1103 (86) 1352 (91)
.3 years duration 89 (7) 67 (5) 181 (14) 130 (9)
Unknown 107 69 722 727
Family history of pancreatic cancer
No 524 (94) 577 (97) 1507 (94) 1620 (96)
Yes 33 (6) 20 (3) 89 (6) 66 (4)
Missing/Not Available 786 848 410 523
Heavy Alcohol Use (.3 drinks per day)
No 1083 (92) 1188 (94) 942 (85) 1224 (90)
Yes 99 (8) 82 (6) 168 (15) 136 (10)
Missing/Not Available 161 175 896 849
Body Mass Index
,18.5 10 (1) 17 (1) 16(1) 17(1)
18.5–25 499 (38) 585 (41) 574(38) 695(40)
25–30 565 (42) 566 (39) 606(40) 723(42)
.30 256 (19) 267 (19) 323(21) 287(17)
Missing/Not Available 13 10 487 487
ABO genotype
O/O 449 (33) 603 (42) 772 (38) 961 (44)
A/O 493 (37) 498 (34) 728 (36) 773 (35)
A/A 135 (10) 102 (7) 167 (8) 159 (7)
B/O 163 (12) 152 (11) 221 (11) 215 (10)
B/B 20 (2) 11 (1) 17 (1) 19 (1)
A/B 81 (6) 78 (5) 97 (5) 80 (4)
1q32 rs3790844
T/T 835 (62) 817 (57) 1319 (66) 1273 (58)
T/C 436 (32) 534 (37) 605 (30) 798 (36)
C/C 72 (5) 94 (7) 82 (4) 137 (6)
5p15 rs401681
C/C 376 (28) 434 (30) 506 (25) 698 (32)
C/T 649 (48) 688 (48) 1029 (51) 1098 (50)
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genetic risk prediction tool, we plotted the estimated lifetime risk
for cases and controls based on a model without genetic factors
and a model with genetic factors. We also calculated the net
reclassification index (NRI) for men and women separately, using
twice the average lifetime risk to define high and low risk
categories [36,37].
Table 1. Cont.
Characteristic Cohort Case-Control
Cases n (%) Controls n (%) Cases n (%) Controls n (%)
T/T 318 (24) 323 (22) 471 (23) 413 (19)
13q22 rs9543325
T/T 448(33) 573 (40) 670 (33) 879 (40)
T/C 672(50) 683 (47) 952 (47) 1027 (47)
C/C 223(17) 189 (13) 382 (19) 302 (14)
doi:10.1371/journal.pone.0072311.t001
Table 2. Association between pancreatic cancer risk and smoking, personal history of diabetes, family history of pancreatic cancer,
alcohol use, body mass index, and known genetic markers.
Characteristic Multivariate Odds Ratio (95% CI) Final Model
Cigarette smoking
Never 1.00
Former 1.22 (1.09, 1.37)
Current 2.20 (1.84, 2.62)
Diabetes mellitus
Never 1.00
.3 years duration (cohort studies) 1.62 (1.15, 2.28)
Unknown (cohort studies) 2.37 (1.64, 3.44)
.3 years duration (case-control studies) 1.77 (1.37, 2.31)
Unknown (case-control studies) 1.10 (0.80, 1.50)
Family history of pancreatic cancer
No
Yes 1.00
Heavy alcohol use (.3 drinks per day) 1.60 (1.20, 2.12)
No 1.00
Yes 1.45 (1.19, 1.76)
Body mass index
,18.5 0.91 (0.54, 1.53)
18.5–25 1.00
25–30 1.08 (0.96, 1.22)
.30 1.26 (1.09, 1.45)
ABO genotype
OO 1.00
AO 1.23 (1.10, 1.37)
AA 1.49 (1.24, 1.79)
BO 1.35 (1.15, 1.59)
BB 1.58 (0.97, 2.59)
AB 1.44 (1.15, 1.81)
1q32 rs3790844 (per risk allele) 1.29 (1.19, 1.40)
5p15 rs401681 (per risk allele) 1.18 (1.10, 1.26)
13q22 rs9543325 (per risk allele) 1.27 (1.18, 1.36)
doi:10.1371/journal.pone.0072311.t002
Pancreatic Cancer Risk Model
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e72311Results
Demographic and risk factor characteristics of study partici-
pants are presented in Table 1. Multivariable adjusted odds ratios
(OR) are presented in Table 2 for the association between the risk
factors included in our model and pancreatic cancer. In our study
population, current smoking was associated with an increased risk
of pancreatic cancer (OR: 2.21, 95% confidence interval [CI]
1.85, 2.64) as were heavy alcohol use (OR 1.37, 95%CI 1.12,
1.68), BMI .30 (OR 1.20, 95%CI 1.04, 1.40), diabetes of .3 year
duration (cohort OR 1.62, 95%CI 1.15, 2.28; case-control OR:
1.77, 95%CI: 1.37, 2.31) and family history of pancreatic cancer
(OR 1.58, 95%CI: 1.19, 2.11). In addition, all four genetic variants
tested were associated with pancreatic cancer (OR for non-O
ABO genotypes ranged from 1.25 to 1.58, and the per-allele odds
ratios for the other three risk SNPs ranged from 1.18 to 1.49).
The area under the ROC curve (AUROC) for a risk model
including only genetic factors was 57% (95%CI 0.55–0.59),
whereas the AUROC for a model including only non-genetic
factors was 58% (95%CI 0.56–0.60). The AUROC for a model
including both genetic and non-genetic factors was 61% (95%CI
0.58–0.63), which was statistically significantly larger than both the
model including only non-genetic factors and the model including
only genetic factors (p,0.0001).
Figure 1 displays the ten-year risks of pancreatic cancer for men
and women in different age categories (51–60, 61–65, 66–70, 71–
75, and 76–80) as a function of risk percentile based on a model
including all risk factors (see Methods). This figure demonstrates
the importance of age as predictor of pancreatic cancer risk, with
risk increasing with increasing age. Only a few individuals had a
10 year absolute risk greater than 2% even if all genetic and non-
genetic risk factors were present.
Figure 2 shows the distribution of estimated lifetime risks for
models that include or do not include genetic factors. Individual
risks varied slightly depending on which model was used to
estimate them. The median difference in lifetime risk estimates
from the model with genetics to the model without genetics was
0.0% (inter-quartile range 20.2% to 0.2%) for both male and
female controls. The NRI comparing the risk model with genetics
to the risk model with no genetic factors was 20.01060.0.008 and
20.02060.011 for men and women respectively (Table 3).
Neither of these estimates was statistically significant (one-sided
p=0.89 and p=0.97, respectively), suggesting that adding genetic
factors to the risk model did not improve clinical utility (defined as
the ability to correctly classify individuals at twice average risk).
As expected, considering that we included established risk
factors for pancreatic cancer in our non-genetic risk model, this
model improved classification relative to a null model that
classified individuals according to their sex-specific average. The
NRI comparing the model with non-genetic risk factors alone to
this null model was 0.02560.010 (one-sided p=0.009) for men
and 0.02660.010 (one-sided p=0.0004) for women. However,
because we evaluated model performance in the same data set
used to build the risk model, these NRIs may be somewhat
overestimated. Moreover, it is unclear whether twice the average
lifetime risk is a clinically actionable threshold: only 8.4% of male
cases (3.5% of female) have more than twice the average lifetime
risk. Most of those identified as high risk will not go on to develop
pancreatic cancer, because the average lifetime risks in both men
and women are low. Twice the average lifetime risk is
261.47%=2.94% in men and 261.31%=2.62% in women,
and 96.3% of men and 96.6% of women above these risk
thresholds will not develop pancreatic cancer in their lifetimes.
The risk models with and without the genetic variables do not
identify subsets of individuals at very high lifetime risks. Using
controls to estimate the distribution of risks in U.S. non-Hispanic
whites, 4/1,000 men and 2/1,000 women would be classified as
having lifetime risk greater than 5%, and none would be classified
as having more than 7% lifetime risk.
Discussion
In this study, we generated a pancreatic cancer risk model based
on established non-genetic and genetic risk factors and calculated
Figure 1. Ten-year risks of pancreatic cancer (y-axis), by age, gender, and risk score percentile (x-axis). The risk score includes smoking
history, heavy alcohol intake, BMI, history of diabetes, family history of pancreatic cancer, ABO genotype and three common genetic variants
associated with pancreatic cancer.
doi:10.1371/journal.pone.0072311.g001
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The risk factors considered were smoking, heavy alcohol intake,
high BMI, diabetes, family history of pancreatic cancer, ABO non-
O blood group and three common genetic variants identified by
GWAS. We found that even if all these known risk factors are
included in the model, most individuals will only be at modestly
increased risks because relatively few individuals have a high
number of risk factors. In addition, we found that the genetic
factors did not add substantively to a risk model based on life-style
factors only, as most individuals remained in the same risk strata.
The low absolute risks observed here for most individuals,
together with the current lack of non-invasive and low cost
screening tools, argue against screening programs for the general
population and underscore the importance of research to identify
novel risk markers. Given the very high mortality rate of
pancreatic cancer, it remains an open question whether future
screening tools could be implemented for individuals in the
population who are at the highest risks, for example individuals
with estimated lifetime risks above 5%. It is important to note that
our model does not account for known high-penetrant genetic
variants or strong familial risk. Individuals with a strong family
history of cancer may benefit from genetic counseling. For such
individuals genetic counseling in conjunction with the PancPRO
[38] model can provide individual level risk estimates.
This study is based on data from a series of cohort and case-
control studies and constitutes the largest risk model analysis of
pancreatic cancer to date. It is also the first risk model for
pancreatic cancer that includes non-genetic risk factors. Our
model can easily be modified to include any new discovered risk
factors.
Our study has several limitations. As with all risk scores that
include genetic variants identified from GWAS, we are most likely
including proxies for the causative genetic variants. Identification
of the causal alleles might result in better performance in our
Figure 2. Reclassification of lifetime risk of pancreatic cancer among cohort controls after adding genetic information to the risk
model.
doi:10.1371/journal.pone.0072311.g002
Table 3. Reclassification of lifetime risk of pancreatic cancer after adding genetic information to the risk model with both genetic
and non-genetic covariates.
Men Women
Risk model with non-
genetic covariates only
Less than twice average
lifetime risk (#2.94%)
More than twice average
lifetime risk (.2.94%)
Less than twice average
lifetime risk (#2.62%)
More than twice average
lifetime risk (.2.62%)
Controls Less than twice 858 11 620 20
average risk
More than twice 9 20 2 7
average risk
Cases Less than twice 716 10 517 11
average risk
More than twice 16 28 7 15
average risk
doi:10.1371/journal.pone.0072311.t003
Pancreatic Cancer Risk Model
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e72311model. Moreover, by focusing on genome-wide significant
markers, we are not including markers that are truly associated
with pancreatic cancer risk but did not achieve statistical
significance. More sophisticated multivariable modeling tech-
niques might be able to use these latent risk markers to improve
predictive ability, but these methods greatly increase the risk of
overfitting and require sample sizes an order of magnitude larger
than the number of cases and controls used in this study [39,40].
We only measured modifiable risk factors during one point in
time. As these risk factors may change over time, our assessment
does not completely capture the cumulative lifetime exposure. We
categorized continuous variables in order to balance model
parsimony and flexibility; however, this approach may have led
to a loss of fine-scale information on exposure distribution. The list
of non-genetic risk factors included here is not complete and future
studies should consider other risk factors. Here we limited the list
of non-genetic factors to well-established non-genetic risk factors
that were assessed in our study population. For example,
information on chronic pancreatitis was not included in these
analyses due to limited availability of pancreatitis data from the
cohorts and the low prevalence of this disease. We included data
from both prospective cohort studies and retrospective case-
control studies. For the prospective data exposure information
may have changed between data collection and occurrence of
pancreatic cancer, while retrospective data can be subject to recall
bias. However, the risk estimates were consistent across study
designs for all exposures other than diabetes mellitus (Table S3).
Our model does not directly measure absolute risk but rather
relies on incidence estimates from the SEER data. We used our
controls data to estimate the distribution of risk factors among
U.S. non-Hispanic whites. The distribution of risk factors in these
controls is likely different than that of the general U.S. population,
as cohort participants are likely healthier and risk factors such as
smoking are less prevalent, and not all studies were based in the
United States. These differences may have affected our risk
estimates in several ways. On the one hand, we may have
underestimated the proportion of U.S. non-Hispanic whites who
would be classified as high risk. On the other hand, by
underestimating the average relative risk (which is inversely
related to the baseline risk), we may have overestimated risk for
individuals with particular genetic and non-genetic profiles. Given
that lifetime risk estimates remained quite low (most less than 5%
and all less than 7.5%) with little variation across the study
population, this possible overestimation does not impact our
conclusions on the utility of this model.
Our analysis is based solely on a population of European
ancestry, so it cannot be generalized to other ethnicities, some of
which have a greater risk of pancreatic cancer [42].
Model fit and reclassification were assessed in the same
populations used to obtain the risk estimates for the model;
therefore, it is possible that the results presented here overestimate
how the risk model would perform in an independent study
population. However, we deliberately chose a parsimonious
approach to modeling, focusing on well-established risk factors,
in order to minimize the risk of overfitting [41]. The risk estimates
for non-genetic covariates observed in this study are consistent
with the existing literature; thus, we would expect our non-genetic
model to perform similarly in other non-Hispanic white popula-
tions. Because the genetic risk markers were discovered in this set
of samples [27,28], the per-allele odds ratios for these markers may
be overestimated due to the ‘‘winner’s curse’’ phenomenon [42].
We used the weighted maximum likelihood method of Zhong and
Prentice to adjust for inflation due to winner’s curse [43]. The
effects at the ABO and 13q22 loci were not appreciably inflated;
the estimates for rs3790844 at chr1q32.1 and rs401681 at 5p15.33
were slightly inflated, with inflation factors of 2% and 7%,
respectively. The AUROCs using the winner’s-curse-adjusted per-
allele odds ratio estimates change only slightly: AUROC=0.55
(0.53,0.47) for the model using risk alleles alone (as compared to
0.57) and c=0.60 (0.58,0.62) for the model with both the risk
alleles and clinical risk factors (as compared to 0.61).
In summary, in a large study sample, we derived an absolute-
risk model for pancreatic cancer and used our model to estimate
risks in the Non-Hispanic White US population. We found that
although all risk factors were individually associated with
pancreatic cancer, the low frequencies of many of the exposures,
along with the small magnitudes of their risks and even that of
their aggregated sum resulted in relatively low ten-year absolute
risks. Thus, absolute risk modeling can identify a subset of the
general population at higher than average risk of pancreatic
cancer, but with the risk factors so far considered, the clinical
utility of such general population models at this time may be
limited.
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